Results 141 to 150 of about 4,697 (156)

Improved characterization of the pharmacokinetics of acalabrutinib and its pharmacologically active metabolite, ACP-5862, in patients with B-cell malignancies and in healthy subjects using a population pharmacokinetic approach

British Journal of Clinical Pharmacology, 2022
Helena Edlund, Karthick Vishwanathan, Shringi Sharma   +2 more
exaly  

EMA Review of Acalabrutinib for the Treatment of Adult Patients with Chronic Lymphocytic Leukemia

Oncologist, 2021
Julio Delgado, Harald Enzmann, Filip Josephson   +2 more
exaly  

A validated chiral chromatographic method for the enantiomeric separation of acalabrutinib

Chirality, 2022
Srinivasu Gunnam, Roshan M Borkar, Radhakrishnanand P   +2 more
exaly  

Bioequivalence and Relative Bioavailability Studies to Assess a New Acalabrutinib Formulation That Enables Coadministration With Proton-Pump Inhibitors

Clinical Pharmacology in Drug Development, 2022
Veerendra munugalavadla, Nataliya Kuptsova-Clarkson, Lianqing Zheng   +2 more
exaly  

Multifaceted Immunomodulatory Effects of the BTK Inhibitors Ibrutinib and Acalabrutinib on Different Immune Cell Subsets – Beyond B Lymphocytes

Frontiers in Cell and Developmental Biology, 2021
Jaeyong Jung, Sining Zhu, Ping Xie
exaly  

People also looked at

Frontiers in Oncology, 2021
William G Wierda, Hussein A Abbas
exaly  

Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial

Lancet, The, 2020
Jeff Sharman, John M Pagel, Ian W. Flinn
exaly  

Inhibition of Bruton tyrosine kinase by acalabrutinib dampens lipopolysaccharide/galactosamine-induced hepatic damage

Biomedicine and Pharmacotherapy, 2020
Hesham Gomaa, Mohamed E Shaker, Mohammad M Al-Sanea   +2 more
exaly  

Assessing the pharmacokinetics of acalabrutinib in the treatment of chronic lymphocytic leukemia.

Expert Opinion on Drug Metabolism and Toxicology, 2021
Jianyong Li
exaly